To assess the clinical usefulness of fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and CT/magnetic resonance (MR) imaging in detecting occult neck metastasis in patients with head and neck squamous cell carcinoma and negative neck palpation findings.
Materials and Methods
This prospective study was approved by the institutional review board, and written informed consent was obtained from all enrolled patients. In total, 91 patients with head and neck squamous cell carcinoma and negative neck palpation findings were assessed prospectively with 
Results
Of 91 patients, 38 (42%) had metastasis in 43 neck sides and 70 levels of the neck.
18
F-FDG PET/CT demonstrated nodal metastasis more sensitively on a per-level basis than did CT/MR imaging (69% vs 39%, P < .001). CT/MR imaging demonstrated nodal metastasis with low sensitivity at all levels (0%-38%) except level II (55%), while 18 F-FDG PET/CT had generally high sensitivity at all levels (63%-100%) except level VI (0%). On a per-patient basis, the sensitivities of 18 F-FDG PET/CT and CT/MR imaging were 71% and 50%, respectively (P = .011).
F-FDG PET/CT accurately depicted CT/MR imaging false-negative findings in nine of 19 patients but yielded false-negative results in 11 patients. Use of 18 F-FDG PET/CT reduced the probability of occult neck metastasis to 12%.
Conclusion

18
F-FDG PET/CT is superior to CT/MR imaging in depicting occult cervical metastatic nodes in patients with negative neck palpation findings. The improved detection and nodal staging may promote appropriate therapeutic planning in these patients.
Gwinnett
Fayetteville F-FDG PET/CT accurately portrayed CT/MRI false-negative findings in nine of 19 patients. However, it also produced false-negative results in 11 patients. The probability of occult neck metastasis was reduced to 12 percent with 18 F-FDG PET/CT. "Although CT/MR imaging is less sensitive than 18 F-FDG PET/CT, it is still required for pretreatment evaluation of primary and neck diseases," wrote Roh and colleagues. "Improved detection and nodal staging with these modalities may promote appropriate therapeutic planning for patients with stage cN0 HNSCC."
